Pancreatic Cancer Clinical Trial
Official title:
A Phase I/ Randomized Phase II Study of Gemcitabine Plus Erlotinib Plus MK-0646; Gemcitabine Plus MK-0646 and Gemcitabine Plus Erlotinib for Patients With Advanced Pancreatic Cancer (IISP#33337)
Objectives:
Primary Objectives:
- Phase I: Determine the maximal tolerated dose (MTD) of MK-0646 in combination with
gemcitabine or gemcitabine plus erlotinib and recommended phase II dose.
- Phase II:
- Assess progression-free survival (PFS) with a) gemcitabine plus MK-0646 b)
gemcitabine plus erlotinib plus MK-0646 and c) gemcitabine plus erlotinib.
- Explore IGF1 tissue level as a predictive biomarker for MK-0646 therapy in phase II
expansion cohort.
Secondary Objectives:
- Assess overall response rate (ORR), treatment toxicity, and overall survival (OS) with
the addition of MK-0646 to gemcitabine or gemcitabine plus erlotinib.
- Correlate PFS and OS with IGF-1, IGFBP-3 levels and the expression of p-IRS, IGF-1R, EMT
biomarkers, Akt, Erk, mTOR, and PI13k in tumor cells.
- To assess the incidence of single nucleotide polymorphisms of the IgF1R pathway related
genes (IGF1, IGF1R, IRS1 and IRS2). These genotypes will be correlated with the clinical
endpoints of this study, including OS, ORR and PFS.
Phase I
The Study Drugs:
MK-0646 is designed to block proteins that are thought to cause cancer cells to grow and
spread. This drug may help slow the growth of tumors.
Gemcitabine is designed to disrupt the growth of cancer cells, which may cause cancer cells
to die.
Erlotinib hydrochloride is designed to block the activity of a protein found on the surface
of many tumor cells that may control the growth and survival of cancer cells. This may stop
cancer cells from growing.
Study Drug Dose Level and Groups:
If you are found to be eligible to take part in this study, you will be assigned to a group
(Arm A or Arm B) based on when you joined the study, how many participants have been enrolled
before you, and on the safety data that is available at that time.
- If you are in Arm A, you will receive MK-0646 and gemcitabine.
- If you are in Arm B, you will receive MK-0646, gemcitabine, and erlotinib hydrochloride.
There are 2 dose levels of MK-0646 in each arm. There will be 3-6 participants enrolled in
each dose level in each arm. Enrollment will begin in Arm A. Arm B will use the same 2 dose
levels as Arm A. If the first dose level of Arm A is found to be tolerable, at least 3
patients will be enrolled in Arm B, Level 1, and then at least 3 patients will be enrolled in
Arm A, Level 2. If Arm B, Level 1 and Arm A, Level 2 can be safely given, the last group of
3-6 patients will be enrolled in Arm B, Level 2. The first group of participants in each arm
will receive the lower dose level. The next group in each arm will receive a higher dose than
the first group, if no intolerable side effects were seen.
The dose of gemcitabine and/or erlotinib hydrochloride will be the same for every group.
Study Drug Administration:
If you are in Arm A, on Days 1, 8, and 15 of each 28-day study cycle, you will receive
gemcitabine through a needle into your vein over about 1 1/2 hours. On Days 1, 8, 15, and 22
of each cycle, you will receive MK-0646 by vein over 1 hour.
If you are in Arm B, you will take erlotinib hydrochloride by mouth once a day (in the
morning) every day. You should take it with about 1 cup (8 oz.) of water 1 hour before or 2
hours after eating. On Days 1, 8, and 15 of each cycle, you will receive gemcitabine by vein
over about 1 1/2 hours. On Days 1, 8, 15, and 22 of each cycle, you will receive MK-0646 by
vein over 1 hour.
Depending upon how well you tolerate gemcitabine, your doctor may decide that you should
receive gemcitabine on Days 1 and 15 instead of Days 1, 8, and 15.
Study Visits:
On Day 1 of Cycle 1, the following tests and procedures will be performed:
- Your medical history will be recorded.
- You will have a performance status evaluation.
- You will be asked to list any drugs you may be taking and if you have experienced any
side effects.
- You will have a physical exam, including measurement of your vital signs and weight.
- Blood (about 2 teaspoons) will be drawn for routine tests.
- Blood (about 1 teaspoon) will be drawn to make sure your body has not created cells to
fight against MK-0646. These cells are called human anti-human antibodies (also known as
HAHA).
On Day 8 of Cycle 1, the following tests and procedures will be performed:
- Your vital signs and weight will be measured.
- Blood (about 2 teaspoons) will be drawn for routine tests.
- You will be asked if you have experienced any side effects.
On Day 15 of Cycle 1, the following tests and procedures will be performed:
- You will have a performance status evaluation.
- You will be asked to list any drugs you may be taking and if you have experienced any
side effects.
- You will have a physical exam, including measurement of your vital signs and weight.
- Blood (about 2 teaspoons) will be drawn for routine tests.
On Day 22 of Cycle 1, the following tests and procedures will be performed:
- Your vital signs and weight will be measured.
- Blood (about 1 teaspoon) will be drawn to test for HAHA.
- You will be asked if you have experienced any side effects.
- Blood (about 2 teaspoons) will be drawn for routine tests.
On Day 1 of Cycles 2 and beyond, the following tests and procedures will be performed:
- You will have a performance status evaluation.
- You will be asked to list any drugs you may be taking and if you have experienced any
side effects.
- You will have a physical exam, including measurement of your vital signs and weight
- Blood (about 2 teaspoons) will be drawn for routine tests.
- Blood (about 1 teaspoon) will be drawn for testing of CA 19-9.
On Days 8 and 15 of Cycles 2 and beyond, the following tests and procedures will be
performed:
- Your vital signs and weight will be measured.
- Blood (about 2 teaspoons) will be drawn for routine tests.
- You will be asked if you have experienced any side effects.
On Day 22 of Cycles 2 and beyond, your vital signs and weight will be measured and you will
be asked if you have experienced any side effects.
On Day 22 of Cycle 2 and every even cycle (Cycles 4, 6, 8, and so on), you will have a CT
scan or MRI scan to check the status of the disease. Blood (about 1 teaspoon) will also be
drawn to test HAHA.
Length of Study:
You may remain on study for as long as you are benefiting. You will be taken off study if the
disease gets worse or you experience intolerable side effects.
End-of-Study Visit:
After you go off study, you will have an end-of-study visit. At this visit, the following
tests and procedures will be performed:
- You will have a performance status evaluation.
- You will be asked to list any drugs you may be taking and if you have experienced any
side effects.
- You will have a physical exam, including measurement of your vital signs and weight.
- You will have a CT scan or MRI scan to check the status of the disease.
- Blood (about 2 teaspoons) will be collected for routine tests.
- Blood (about 1 teaspoon) will be drawn to test HAHA.
- Blood (about 1 teaspoon) will be drawn to test CA 19-9.
At Weeks 4, 8, and 12 after the end of study visit, blood (about 1 teaspoon) will be drawn to
test HAHA.
Long-Term Follow Up:
Once you are off study, every 3 months from then on, the study staff will ask you how you are
doing, either in the clinic or by telephone. If you are called, the phone call will take
about 10-15 minutes.
This is an investigational study. MK-0646 is not FDA approved or commercially available. At
this time, MK-0646 is only being used in research. Gemcitabine is FDA approved and
commercially available for the treatment of pancreatic cancer. Erlotinib hydrochloride is FDA
approved and commercially available for the treatment of pancreatic cancer in combination
with gemcitabine.
Up to 100 patients will take part in this study. All will be enrolled at MD Anderson.
Phase II:
The Study Drugs:
MK-0646 is designed to block proteins that are thought to cause cancer cells to grow and
spread. This drug may help slow the growth of tumors.
Gemcitabine is designed to disrupt the growth of cancer cells, which may cause cancer cells
to die.
Erlotinib hydrochloride is designed to block the activity of a protein found on the surface
of many tumor cells that may control the growth and survival of cancer cells. This may stop
cancer cells from growing.
Study Groups:
If you are found to be eligible to take part in this study, you will be randomly assigned (as
in the roll of the dice) into 1 of 3 groups.
- If you are in Arm A, you will receive gemcitabine and MK-0646.
- If you are in Arm B, you will receive erlotinib hydrochloride, gemcitabine, and MK-0646.
- If you are in Arm C, you will receive erlotinib hydrochloride and gemcitabine.
Study Drug Administration:
If you are in Arm A, on Days 1, 8, and 15 of each 28-day study cycle, you will receive
gemcitabine through a needle into your vein over about 1 1/2 hours as an infusion once a week
for 3 weeks. On Days 1, 8, 15, and 22 of each cycle, you will receive MK-0646 by vein over 1
hour.
If you are in Arm B, you will take erlotinib hydrochloride by mouth once (in the morning)
every day. On Days 1, 8, and 15 of each cycle, you will receive gemcitabine by vein over
about 1 1/2 hours. On Days 1, 8, 15, and 22 of each cycle, you will receive MK-0646 by vein
over 1 hour.
If you are in Arm C, you will take erlotinib hydrochloride by mouth once (in the morning)
every day. On Days 1, 8, and 15 of each cycle, you will receive gemcitabine by vein over
about 1 1/2 hours.
If you are taking erlotinib hydrochloride, you should take it with about 1 cup (8 oz.) of
water 1 hour before or 2 hours after eating.
Depending upon how well you tolerate gemcitabine, your doctor may decide that you should
receive gemcitabine on Days 1 and 15 instead of Days 1, 8, and 15.
Study Visits:
On Day 1 of Cycle 1, the following tests and procedures will be performed:
- Your medical history will be recorded.
- You will have a performance status evaluation.
- You will be asked to list any drugs you may be taking and if you have experienced any
side effects.
- You will have a physical exam, including measurement of your vital signs and weight.
- Blood (about 2 teaspoons) will be drawn for routine tests.
- If you are assigned to receive MK-0646, blood (about 1 teaspoon) will be drawn to make
sure your body has not created cells to fight against MK-0646. These cells are called
human anti-human antibodies (also known as HAHA).
On Day 8 of Cycle 1, the following tests and procedures will be performed:
- Your vital signs and weight will be measured.
- Blood (about 2 teaspoons) will be drawn for routine tests.
- You will be asked if you have experienced any side effects.
On Day 15 of Cycle 1, the following tests and procedures will be performed:
- You will have a performance status evaluation.
- You will be asked to list any drugs you may be taking and if you have experienced any
side effects.
- You will have a physical exam, including measurement of your vital signs and weight.
- Blood (about 2 teaspoons) will be drawn for routine tests.
On Day 22 of Cycle 1, the following tests and procedures will be performed if you are
receiving MK-0646:
- Your vital signs and weight will be measured
- Blood (about 1 teaspoon) will be drawn to test for HAHA.
- You will be asked if you have experienced any side effects.
On Day 1 of Cycles 2 and beyond, the following tests and procedures will be performed:
- You will have a performance status evaluation.
- You will be asked about any other drugs you may be taking and if you have experienced
any side effects.
- You will have a physical exam, including measurement of your vital signs and weight
- Blood (about 2 teaspoons) will be drawn for routine tests.
- Blood (about 1 teaspoon) will be drawn for testing of CA 19-9.
On Days 8 and 15 of Cycles 2 and beyond, the following tests and procedures will be
performed:
- Your vital signs and weight will be measured.
- Blood (about 2 teaspoons) will be drawn for routine tests.
- You will be asked if you have experienced any side effects.
On Day 22 of Cycles 2 and beyond, your vital signs and weight will be measured, (if you are
receiving MK-0646). and you will be asked if you have experienced any side effects.
On Day 22 of Cycle 2 and every even cycle (Cycles 4, 6, 8, and so on), you will have a CT
scan or MRI scan to check the status of the disease. Blood (about 1 teaspoon) will be also be
drawn to test HAHA if you are receiving MK-0646.
Length of Study:
You may remain on study for as long as you are benefiting. You will be taken off study if the
disease gets worse or you experience intolerable side effects.
If you are in Arm C (erlotinib and gemcitabine) and the disease gets worse, you may be
allowed to join Arm B (gemcitabine, erlotinib, and MK-0646).
End-of-Study Visit:
After you go off study, you will have an end-of-study visit. At this visit the following
tests and procedures will be performed:
- You will have a performance status evaluation.
- You will be asked to list any drugs you may be taking and if you have experienced any
side effects.
- You will have a physical exam, including measurement of your vital signs and weight.
- You will have a CT scan or MRI scan to check the status of the disease.
- Blood (about 2 teaspoons) will be collected for routine tests.
- Blood (about 1 teaspoon) will be drawn for testing of CA 19-9.
- Blood (about 1 teaspoon) will be drawn for testing to test HAHA if you are receiving
MK-0646.
At Weeks 4, 8, and 12 after the end of study visit, blood (about 1 teaspoon) will be drawn to
test HAHA if you were receiving MK-0646.
Long-Term Follow Up:
Once you are off study, every 3 months from then on, the study staff will ask you how you are
doing, either in the clinic or by telephone. If you are called, this phone call will take
about 10-15 minutes.
This is an investigational study. MK-0646 is not FDA approved or commercially available. At
this time, MK-0646 is only being used in research. Gemcitabine is FDA approved and
commercially available for the treatment of pancreatic cancer. Erlotinib hydrochloride is FDA
approved and commercially available for the treatment of pancreatic cancer in combination
with gemcitabine.
Up to 100 patients will take part in this study. All will be enrolled at MD Anderson.
Phase II Expansion Cohort:
The Study Drugs:
MK-0646 is designed to block proteins that are thought to cause cancer cells to grow and
spread. This drug may help slow the growth of tumors.
Gemcitabine is designed to disrupt the growth of cancer cells, which may cause cancer cells
to die.
Study Treatments:
If you are found to be eligible to take part in this study, you will receive gemcitabine and
MK-0646.
Study Drug Administration:
On Days 1, 8, and 15 of each 28-day study cycle, you will receive gemcitabine through a
needle into your vein over about 1 1/2 hours as an infusion once a week for 3 weeks. On Days
1, 8, 15, and 22 of each cycle, you will receive MK-0646 by vein over 1 hour.
Depending upon how well you tolerate gemcitabine, your doctor may decide that you should
receive gemcitabine on Days 1 and 15 instead of Days 1, 8, and 15.
Study Visits:
On Day 1 of Cycle 1, the following tests and procedures will be performed:
- Your medical history will be recorded.
- You will have a performance status evaluation.
- You will be asked to list any drugs you may be taking and if you have experienced any
side effects.
- You will have a physical exam, including measurement of your vital signs and weight.
- Blood (about 2 teaspoons) will be drawn for routine tests.
On Day 8 of Cycle 1, the following tests and procedures will be performed:
- Your vital signs and weight will be measured.
- Blood (about 2 teaspoons) will be drawn for routine tests.
- You will be asked if you have experienced any side effects.
On Day 15 of Cycle 1, the following tests and procedures will be performed:
- You will have a performance status evaluation.
- You will be asked to list any drugs you may be taking and if you have experienced any
side effects.
- You will have a physical exam, including measurement of your vital signs and weight.
- Blood (about 2 teaspoons) will be drawn for routine tests.
On Day 22 of Cycle 1, the following tests and procedures will be performed if you are
receiving MK-0646:
- Your vital signs and weight will be measured
- You will be asked if you have experienced any side effects
- Blood (about 1 tablespoon) will be drawn for biomarker testing.
On Day 1 of Cycles 2 and beyond, the following tests and procedures will be performed:
- You will have a performance status evaluation.
- You will be asked about any other drugs you may be taking and if you have experienced
any side effects.
- You will have a physical exam, including measurement of your vital signs and weight
- Blood (about 2 teaspoons) will be drawn for routine tests.
- Blood (about 1 teaspoon) will be drawn for testing of CA 19-9.
On Days 8 and 15 of Cycles 2 and beyond, the following tests and procedures will be
performed:
- Your vital signs and weight will be measured.
- Blood (about 2 teaspoons) will be drawn for routine tests.
- You will be asked if you have experienced any side effects.
On Day 22 of Cycles 2 and beyond, your vital signs and weight will be measured and you will
be asked if you have experienced any side effects.
On Day 22 of Cycle 2 and every even cycle (Cycles 4, 6, 8, and so on), you will have a CT
scan or MRI scan to check the status of the disease.
Length of Study:
You may remain on study for as long as you are benefiting. You will be taken off study if the
disease gets worse or you experience intolerable side effects.
End-of-Study Visit:
After you go off study, you will have an end-of-study visit. At this visit the following
tests and procedures will be performed:
- You will have a performance status evaluation.
- You will be asked to list any drugs you may be taking and if you have experienced any
side effects.
- You will have a physical exam, including measurement of your vital signs and weight.
- You will have a CT scan or MRI scan to check the status of the disease.
- Blood (about 2 teaspoons) will be collected for routine tests.
- Blood (about 1 teaspoon) will be drawn for testing of CA 19-9.
Long-Term Follow Up:
Once you are off study, every 3 months from then on, the study staff will ask you how you are
doing, either in the clinic or by telephone. If you are called, this phone call will take
about 10-15 minutes.
This is an investigational study. MK-0646 is not FDA approved or commercially available. At
this time, MK-0646 is only being used in research. Gemcitabine is FDA approved and
commercially available for the treatment of pancreatic cancer.
Up to 100 patients total will take part in this study. All will be enrolled at MD Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
| Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
| Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
| Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|